Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus Clinical Trial

Official title:

Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03052400
• Other study ID #: 16-04-2482
• Status: Terminated
• Phase: Phase 2
• Start date: February 3, 2017
• Est. completion date: May 31, 2021

Study information

• Verified date: April 2023
• Source: Charles Drew University of Medicine and Science
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Randomized, double blind, placebo-controlled clinical trial examining the efficacy and safety of mifepristone 600 mg daily in male subjects with type 2 diabetes mellitus, not associated with Cushing's syndrome

Description:

Randomized, double blind, placebo-controlled clinical trial examining the efficacy and safety of mifepristone 600 mg daily in male subjects with type 2 diabetes mellitus, not associated with Cushing's syndrome, and sub-optimally controlled on basal insulin, with or without prandial insulin and/or maximally-tolerated doses of metformin.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: May 31, 2021
• Est. primary completion date: March 31, 2021
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion criteria:

• Males

• Age 18-65 inclusive

• Established T2DM for = 1 year

• Taking stable doses (= 20% change in total daily insulin dose within 2 months prior to screening) of basal insulin, with or without prandial insulin (total daily dose must be = 200 units)

• Baseline hemoglobin A1c (HbA1c) 8.0%-10.5%

Exclusion criteria:

• No use of any anti-hyperglycemic agents (oral or injectable) other than metformin or insulin

• No history or clinical suspicion of type 1 diabetes mellitus

• No concurrent chronic use of any corticosteroids by any route and for any indication, or concurrent conditions that may require the initiation of glucocorticoids during the study

• No concurrent lipid-lowering medications whose levels are dependent on CYP3A pathway clearance (e.g., simvastatin, lovastatin, atorvastatin, fluvastatin and rosuvastatin) should either be washed out for at least one month prior to enrollment and/or switched to alternative LDL-cholesterol lowering agents (e.g., pravastatin or ezetimibe) for at least one month.

• No contraindications or known intolerance to mifepristone

• No concurrent use of strong CYP3A inhibitors (e.g., cyclosporine, ergotamine, fentanyl, quinidine, sirolimus, tacrolimus, imidazole antifungals, HIV protease inhibitors, certain macrolide antibiotics)

• No concurrent use of CYP3A inducers (e.g., phenytoin, phenobarbital, carbamazepine, rifampin)

• No concurrent use of medications that may prolong the QT interval (e.g., selected antipsychotics and antidepressants, quinolone antibiotics)

• No daily use of warfarin or non-steroidal anti-inflammatory agents

• Baseline K+ and Mg+2 within the laboratory normal ranges, with or without oral K+ and/or Mg+2 supplementation

• Fasting plasma glucose (FPG) averaging < 280 mg/dL and without polyuria or polydipsia

• No symptomatic hypoglycemia averaging > once per day

• Able and willing to perform self-monitoring of blood glucose (SMBG)

• Mean BP < 140 mmHg systolic or 90 mm Hg diastolic

• Baseline LDL-cholesterol < 200 mg/dL if on lipid-lowering therapy or < 250 mg/dL while not on lipid-lowering therapy

• Fasting triglycerides = 500 mg/dL if on lipid-lowering therapy

• HDL-cholesterol = 25 mg/dL

• No known history of prostate cancer, or elevated level of prostate-specific antigen (PSA) at screening

• Estimated GFR = 30 mL/min

• No concurrent endocrinopathies that have not been stabilized with replacement or other definitive therapies (including known adrenal insufficiency regardless of replacement therapy, cortisol < 5 µg/dL at screening)

• No active hemolytic anemias or hemoglobin variants that render the measurement of HbA1c potentially unreliable

• No other clinically significant hepatic, cardiovascular (including known personal or family history of, or risk factors for long-QT syndrome, QTcF prolongation on ECG > 500 ms), infectious (including HIV or any viral hepatitis), inflammatory, neoplastic or other systemic disease that may contraindicate the change of lipid-lowering therapy, renders mifepristone unsafe, or otherwise confounds data interpretation

• Subjects not likely to start other drugs that may influence the study's outcomes (e.g., weight loss agents)

• Subjects who are able and willing to comply with all components of the study protocol, attend all scheduled follow-up visits, or who do not present other foreseeable barriers that might make the implementation of the protocol problematic or confound data interpretation

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Insulin Resistance
• Type 2 Diabetes Mellitus

Intervention

Drug:
• Mifepristone 600 mg daily
Glucocorticoid receptor antagonist
• Placebo
Matching placebo

Locations

Country	Name	City	State
United States	Charles Drew University of Medicine and Science	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
Charles Drew University of Medicine and Science

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hemoglobin A1c	Glycemic lowering	Baseline to 3 months
Secondary	Weight	Weight in kg	Baseline to 3 months
Secondary	Body Mass Index	Body mass index in kg/m^2	Baseline to 3 months
Secondary	Systolic BP	Systolic blood pressure	Baseline to 3 months
Secondary	Diastolic BP	Diastolic blood pressure	Baseline to 3 months
Secondary	LDL-cholesterol	Low-density lipoprotein cholesterol	Baseline to 3 months
Secondary	Cortisol	Serum cortisol level (AM)	Baseline to 3 months
Secondary	ACTH	Serum adrenocorticotrophic hormone level (AM)	Baseline to 3 months
Secondary	Uric Acid	Serum uric acid level	Baseline to 3 months
Secondary	PSA	Prostate-specific antigen level	Baseline to 3 months
Secondary	Hypoglycemic Events	Symptomatic mild and severe hypoglycemic events	Baseline to 3 months
Secondary	Adverse Events	Non-hypoglycemia-related adverse events	Baseline to 3 months
Secondary	Basal Insulin Dose	Total daily basal insulin dosage	Baseline to 3 months